Company Ticker News July 22, 2021Biogen's controversial Alzheimer's drug generates $2 million in first few weeks after approval 0 0 Share
Video News July 22, 2021Wedbush: Cautious on Biogen and its Alzheimer's drug due to uncertainty around cost, reimbursement a 0 0 Share
Company Ticker News July 22, 2021Roche Is Discussing Alzheimer's Drug With FDA Following Regulators Controversial Approval Of Biogen's Aduhelm, CEO Says 0 0 Share
Press Release July 22, 2021An open letter to the Alzheimer's disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D. 0 0 Share
Company Ticker News July 22, 2021Biogen profit tumbles 71% on rising competition to multiple sclerosis drug 0 0 Share
Company Ticker News July 21, 2021Biogen, Mirimus Team Up For RNAi-Based Therapeutics For Neurological Indications 0 0 Share
Press Release July 21, 2021Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications 0 0 Share
